Vitamin shoppe, inc. (VSI)
CashFlow / Yearly
Dec'18Dec'17Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities:
Net income (loss)

-3,752

-252,151

-252,151

24,964

53,171

61,241

66,546

60,825

44,864

29,246

12,666

Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization of fixed assets, intangible assets and finance leases right-of-use assets

42,114

39,204

39,204

38,780

38,495

34,219

28,026

23,076

20,300

21,112

21,095

Impairment charges on goodwill

0

210,633

210,600

32,636

0

0

-

-

-

-

-

Impairment charges on intangible assets

8,174

59,405

59,405

6,594

0

0

-

-

325

0

-

Impairment charges on fixed assets

11,057

6,658

6,658

797

1,177

419

-

730

887

1,326

-

Loss on sale of FDC Vitamins, LLC

-203

-

0

0

-

-

-

-

-

-

-

Amortization of Debt Issuance Costs

604

898

898

957

237

164

96

258

372

740

1,227

Contingent consideration for acquisition of FDC Vitamins, LLC

-

0

-

-

959

-959

-

-

-

-

-

Gain on insurance recoveries

-

-

-

-

-

-

1,079

-

-

-

-

Gain (Loss) on Extinguishment of Debt

16,902

-

0

0

-

-

-

-

-

-

-

Amortization of Debt Discount (Premium)

3,170

4,781

4,781

4,690

223

0

-

-

-

-

-

Loss on extinguishment of debt, net of premium on Note redemption

-

-

-

-

-

-

-

-

-635

-1,349

-1,568

Loss on disposal of fixed assets

-

-

-

-

-

-

-

-711

-15

-187

-130

Amortization of unrealized loss on terminated swap

-

-

-

-

-

-

-

-

-

1,079

565

Deferred income taxes

5,619

-19,834

-19,834

-13,683

-1,364

-3,950

545

-6,055

-1,476

1,166

-4,995

Deferred rent

3,881

2,431

2,431

3,226

2,294

503

-810

-292

-1,068

1,528

3,041

Equity compensation expense

2,663

6,122

6,122

6,292

5,491

6,901

8,333

6,500

5,166

4,076

3,040

Issuance of shares for services rendered

0

0

0

333

167

0

-

-

-

-

-

Proceeds from insurance recoveries

-

-

-

-

-

-

757

-

-

-

-

Tax benefits on exercises of equity awards

-792

-1,017

-1,017

-739

-509

5,363

2,074

12,332

1,108

-12,002

-352

Changes in operating assets and liabilities:
Accounts receivable

1,458

-3,932

-1,102

-70

-2,939

-1,499

-

-

-

-

-

Inventories

-33,052

-10,460

-10,573

13,078

38,284

2,458

13,429

16,201

10,189

5,214

-800

Prepaid expenses and other current assets

-11,691

5,916

5,916

8,521

-3,889

-3,782

15,668

-558

4,259

-12,762

-800

Other long-term assets

16

598

598

-116

139

-2,441

968

629

395

193

217

Accounts payable

-7,104

-15,595

-12,916

26,522

-3,709

-9,869

11,688

2,226

3,978

-6,419

1,336

Deferred sales

-255

-

501

-15,277

-

-

-

-

-

-

-

Deferred sales

-

501

-

-

-2,011

787

734

2,053

2,930

1,543

1,347

Accrued expenses and other current liabilities

4,873

7,047

7,047

2,921

394

8,483

-1,416

15,842

13,641

2,360

3,553

Other long-term liabilities

-497

2,094

2,094

747

2,735

1,395

-1,779

496

379

538

-2,170

Net cash provided by operating activities

90,147

56,227

56,189

93,373

60,667

100,147

81,122

78,350

77,133

55,184

43,434

Cash flows from investing activities:
Capital expenditures

28,138

55,020

55,020

40,068

39,403

42,957

42,782

30,775

25,046

18,356

21,244

Net proceeds on sale of FDC Vitamins, LLC

14,847

-

0

0

-

-

-

-

-

-

-

Acquisition of FDC Vitamins, LLC

-

0

-

-

-487

81,538

-

-

-

-

-

Trademarks and other intangible assets

372

428

428

291

514

689

648

399

-

92

37

Net cash used in investing activities

-13,663

-55,448

-55,448

-40,359

-39,430

-125,184

-93,650

-31,174

-25,046

-18,448

-21,281

Proceeds from insurance recoveries

-

-

-

-

-

-

322

-

-

-

-

Cash flows from financing activities:
Borrowings under revolving credit facility

163,000

118,000

118,000

82,000

47,000

15,000

-

-

12,000

38,000

8,594

Repayments of borrowings under revolving credit facility

175,000

117,000

117,000

79,000

47,000

7,000

-

-

30,000

20,000

25,594

Purchases of convertible notes

63,891

-

0

0

-

-

-

-

-

-

-

Proceeds from issuance of convertible notes

-

0

-

-

143,750

0

-

-

-

-

-

Debt issuance costs on convertible notes

-

0

-

-

4,593

0

-

-

-

-

-

Bond hedge purchase

-

0

-

-

26,407

0

-

-

-

-

-

Proceeds from sale of warrants

-

0

-

-

12,966

0

-

-

-

-

-

Contingent consideration payment for acquisition of FDC Vitamins, LLC

-

0

-

-

4,041

0

-

-

-

-

-

Bank overdraft

601

-3,265

-3,265

-1,041

6,973

0

-

-

-

-

-

Borrowings under term loan

-

-

-

-

-

-

-

-

25,000

0

-

Repayment of borrowings under term loan

-

-

-

-

-

-

-

-

25,000

0

-

Payments of capital lease obligations

477

451

451

207

80

152

135

1,052

1,732

1,611

1,334

Redemption of long term debt (Notes)

-

-

-

-

-

-

-

-

55,106

65,000

44,894

Redemption of preferred shares

-

-

-

-

-

-

-

-

-

-

72,535

Proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

-

755

Proceeds from issuance of common stock during offering, net

-

-

-

-

-

-

-

-

-

-

121,209

Payments for expenses related to the offering

-

-

-

-

-

-

-

-

-

-

1,700

Proceeds from exercises of common stock options

0

1,511

1,500

90

1,352

9,393

3,487

11,236

6,087

16,866

686

Issuance of shares under employee stock purchase plan

290

469

469

823

892

923

849

721

917

359

-

Purchases of treasury stock

304

580

580

1,205

2,530

2,415

280

-

-

-

-

Purchases of shares under Share Repurchase Programs

0

0

0

66,011

146,108

57,815

-

-

-

-

-

Tax benefits on exercises of equity awards

0

0

0

-739

-509

5,363

2,074

12,332

1,108

12,002

352

Deferred financing fees and other

-

346

-

-

93

174

532

-

575

181

518

Other financing activities

17

-

-346

-14

-

-

-

-

-

-

-

Net cash used in financing activities

-75,764

-1,662

-1,662

-65,304

-18,428

-36,877

5,463

23,237

-67,301

-19,565

-14,979

Effect of exchange rate changes on cash and cash equivalents

1

35

35

19

129

44

-67

1

-

0

-

Net increase (decrease) in cash and cash equivalents

721

-848

-886

-12,271

2,938

-61,870

-7,132

70,414

-15,214

17,171

7,174

Supplemental disclosures of cash flow information:
Interest paid

3,186

3,953

3,953

3,715

440

249

390

362

2,401

7,628

17,279

Income taxes paid (refunded)

-14,915

-

6,610

33,655

-

-

-

-

-

-

-

Income taxes paid

-

6,610

-

-

33,659

37,652

57,064

30,817

28,199

6,732

11,258

Supplemental disclosures of non-cash investing activities:
Liability for purchases of property and equipment

1,935

4,457

4,457

4,630

7,497

8,379

7,106

5,064

4,991

1,648

1,525

Assets acquired under capital leases

0

891

891

1,589

0

0

314

264

-

459

792

Assets acquired under tenant incentives

0

2,986

2,986

0

0

-

-

-

-

-

-